pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Fentanyl
drug
save

fentanyl ER

Marketedupdated 3mo ago
by Actavis Elizabeth LLC
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval674 co-mentions · 246 sources
  • drugfentanyl CR641 co-mentions · 294 sources
  • drugFENTANYL-75641 co-mentions · 294 sources
  • drugfentanyl641 co-mentions · 294 sources
  • drugFENTANYL-37641 co-mentions · 294 sources
  • drugActiq240 co-mentions · 183 sources
  • drugSUBLIMAZE PRESERVATIVE FREE238 co-mentions · 183 sources
  • drugEffentora234 co-mentions · 183 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 30 investigational indications.

all catalysts(54)

approval · 51
Jan 28, 2005
approval
$NIU2.0500-2.84%
22y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
May 4, 2005
approval
$NIU2.0500-2.84%
21y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Sep 6, 2005
approval
$NIU2.0500-2.84%
21y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Jan 23, 2007
approval
$NIU2.0500-2.84%
20y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Jan 23, 2007
approval
$NIU2.0500-2.84%
20y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
May 20, 2008
approval
$NIU2.0500-2.84%
18y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Feb 9, 2011
approval
16y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
Jul 9, 2012
approval
14y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
Jul 9, 2012
approval
$NIU2.0500-2.84%
14y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Jul 9, 2012
approval
$NIU2.0500-2.84%
14y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Jul 9, 2012
approval
14y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
Jul 10, 2012
approval
$NIU2.0500-2.84%
14y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Apr 15, 2013
approval
13y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
Apr 15, 2013
approval
$NIU2.0500-2.84%
13y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Jun 16, 2014
approval
12y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
Jun 20, 2014
approval
$NIU2.0500-2.84%
12y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Aug 19, 2014
approval
$NIU2.0500-2.84%
12y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Aug 19, 2014
approval
12y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
Jun 11, 2015
approval
11y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
Jun 26, 2015
approval
$NIU2.0500-2.84%
11y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Jun 26, 2015
approval
11y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
Jul 8, 2015
approval
$NIU2.0500-2.84%
11y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Apr 20, 2016
approval
10y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
Apr 20, 2016
approval
$NIU2.0500-2.84%
10y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Sep 30, 2016
approval
$NIU2.0500-2.84%
10y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Sep 30, 2016
approval
10y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
May 26, 2017
approval
$NIU2.0500-2.84%
9y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
May 26, 2017
approval
9y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
Sep 18, 2018
approval
8y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
Sep 18, 2018
approval
$NIU2.0500-2.84%
8y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
May 6, 2020
approval
6y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
May 6, 2020
approval
6y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
May 6, 2020
approval
6y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
May 6, 2020
approval
6y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
May 6, 2020
approval
6y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
Dec 8, 2023
approval
3y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
Dec 14, 2023
approval
$NIU2.0500-2.84%
3y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Dec 14, 2023
approval
$NIU2.0500-2.84%
3y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Dec 14, 2023
approval
$NIU2.0500-2.84%
3y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Dec 14, 2023
approval
$NIU2.0500-2.84%
3y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Dec 14, 2023
approval
$NIU2.0500-2.84%
3y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Dec 15, 2023
approval
3y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
Dec 15, 2023
approval
$NIU2.0500-2.84%
3y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Dec 15, 2023
approval
3y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
Oct 31, 2024
approval
$NIU2.0500-2.84%
2y ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Oct 31, 2024
approval
2y ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
Dec 22, 2025
approval
8mo ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
Dec 22, 2025
approval
$NIU2.0500-2.84%
8mo ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Dec 22, 2025
approval
8mo ago
FENTANYL-75 (FENTANYL) — FDA approval
fentanyl ER
→
Dec 22, 2025
approval
$NIU2.0500-2.84%
8mo ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
Dec 22, 2025
approval
$NIU2.0500-2.84%
8mo ago
FENTANYL-37 (FENTANYL) — FDA approval
fentanyl ER
→
phase 2 completion · 2
Apr 27, 2026
phase 2 completion
4mo ago
Konya City Hospital — fentanyl (Phase II Trial Completion)
fentanyl ER
→
Apr 28, 2026
phase 2 completion
4mo ago
KS Hegde Medical Academy — fentanyl (Phase II Trial Completion)
fentanyl ER
→
phase iv trial initiation · 1
Apr 26, 2026
phase iv trial initiation
4mo ago
Kalpana Chawla Government Medical College — fentanyl (Phase IV Trial Initiation)
fentanyl ER
→
view all 54 catalysts →

Trials studying fentanyl ER

  • phase2A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockadenot yet recruitingn=16
  • N/AIntercostal Nerve Cryoablation Versus Epidural Analgesia for Nuss Repair of Pectus Excavatumcompletedn=50
  • phase4Premedication for Less Invasive Surfactant Administration Study (PRELISA)completedn=58
  • phase1A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumorsrecruitingn=100
  • phase1Buprenorphine-Fentanyl Interaction Studycompletedn=22
  • phase1Bioequivalence Study of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Participantscompletedn=56
  • phase1A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participantscompletedn=52
  • phase4Programmed Intermittent Epidural Bolus (PIEB) Techniques for Labour Analgesiacompletedn=136
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Jan 25, 2027
163 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (68)

  • Apr 27, 2030formulationUS 84869723.7y
  • Apr 27, 2030formulationUS 84869723.7y
  • Apr 27, 2030formulationUS 84869723.7y
  • Apr 27, 2030formulationUS 84869723.7y
  • Apr 27, 2030formulationUS 84869723.7y
  • Apr 27, 2030formulationUS 84869723.7y
  • Apr 27, 2030formulationUS 84869723.7y
  • Apr 27, 2030method-of-use (U-55)US 84869733.7y
  • Apr 27, 2030method-of-use (U-55)US 84869733.7y
  • Apr 27, 2030method-of-use (U-55)US 84869733.7y
  • Apr 27, 2030method-of-use (U-55)US 84869733.7y
  • Apr 27, 2030method-of-use (U-55)US 84869733.7y
  • Apr 27, 2030method-of-use (U-55)US 84869733.7y
  • Apr 27, 2030method-of-use (U-55)US 84869733.7y
  • Jan 25, 2027formulationUS 10016403163d
  • Jan 25, 2027formulationUS 10016403163d
  • Jan 25, 2027formulationUS 10016403163d
  • Jan 25, 2027formulationUS 10016403163d
  • Jan 25, 2027formulationUS 10016403163d
  • Jan 25, 2027formulationUS 10016403163d
  • Jan 25, 2027formulationUS 10016403163d
  • Jan 25, 2027formulationUS 10610523163d
  • Jan 25, 2027formulationUS 10610523163d
  • Jan 25, 2027formulationUS 10610523163d
  • Jan 25, 2027formulationUS 10610523163d
  • Jan 25, 2027formulationUS 10610523163d
  • Jan 25, 2027formulationUS 10610523163d
  • Jan 25, 2027formulationUS 10610523163d
  • Jan 25, 2027formulationUS 8835459163d
  • Jan 25, 2027formulationUS 8835459163d
  • Jan 25, 2027formulationUS 8835459163d
  • Jan 25, 2027formulationUS 8835459163d
  • Jan 25, 2027formulationUS 8835459163d
  • Jan 25, 2027formulationUS 8835460163d
  • Jan 25, 2027formulationUS 8835460163d
  • Jan 25, 2027formulationUS 8835460163d
  • Jan 25, 2027formulationUS 8835460163d
  • Jan 25, 2027formulationUS 8835460163d
  • Jan 25, 2027formulationUS 8835460163d
  • Jan 25, 2027formulationUS 8835460163d
  • Jan 25, 2027formulationUS 9241935163d
  • Jan 25, 2027formulationUS 9241935163d
  • Jan 25, 2027formulationUS 9241935163d
  • Jan 25, 2027formulationUS 9241935163d
  • Jan 25, 2027formulationUS 9241935163d
  • Jan 25, 2027formulationUS 9241935163d
  • Jan 25, 2027formulationUS 9241935163d
  • Jan 25, 2027formulationUS 9289387163d
  • Jan 25, 2027formulationUS 9289387163d
  • Jan 25, 2027formulationUS 9289387163d
  • Jan 25, 2027formulationUS 9289387163d
  • Jan 25, 2027formulationUS 9289387163d
  • Jan 25, 2027formulationUS 9289387163d
  • Jan 25, 2027formulationUS 9289387163d
  • Jan 25, 2027formulationUS 9642797163d
  • Jan 25, 2027formulationUS 9642797163d
  • Jan 25, 2027formulationUS 9642797163d
  • Jan 25, 2027formulationUS 9642797163d
  • Jan 25, 2027formulationUS 9642797163d
  • Jan 25, 2027formulationUS 9642797163d
  • Jan 25, 2027formulationUS 9642797163d
  • Jan 25, 2027formulationUS 9642844163d
  • Jan 25, 2027formulationUS 9642844163d
  • Jan 25, 2027formulationUS 9642844163d
  • Jan 25, 2027formulationUS 9642844163d
  • Jan 25, 2027formulationUS 9642844163d
  • Jan 25, 2027formulationUS 9642844163d
  • Jan 25, 2027formulationUS 9642844163d

News(10)

  • Two years after rules overhaul, have methadone clinics really changed?
    Methadone clinics don't have to be as rigid in how they dispense opioid addiction medicine. Some, though not all, are changing their ways.
    stat · 12h ago
  • Syphilis spreads while researchers contend with federal constraints and a drug shortage
    At the San Diego-Tijuana border, syphilis spreads while researchers contend with federal constraints and a drug shortage.
    stat · 14d ago
  • Anthony Fauci’s pandemic-era diary entries
    New data on American substance use, concerns of a global HIV resurgence, and more health news from Morning Rounds
    stat · 17d ago
  • Opinion: The shortage of forensic pathologists is hurting justice, public health, and families
    It’s time to solve the case of the missing pathologist.
    stat · 1mo ago
  • Six of the biggest health news stories today
    High-end infant formula scrutiny, the spread of synthetic opioids, and more health news from Morning Rounds
    stat · 1mo ago
  • Super-potent synthetic opioids called nitazenes are spreading across the U.S.
    Overdose deaths confirmed to involve nitazenes have risen sharply in the U.S., from 27 in 2020 to 409 in 2024, according to the CDC
    stat · 1mo ago
  • New infant botulism outbreak puts fancy formulas under scrutiny
    A new infant botulism outbreak puts fancy formulas that position their products as safer than other options under scrutiny.
    stat · 1mo ago
  • RFK Jr. presents $700 million in mental health funding, but experts say grants aren’t new
    RFK Jr. presents funding intended to address mental illness and addiction, particularly among homeless people.
    stat · 1mo ago
  • FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
    The U.S. Food and Drug Administration (FDA) today approved another over-the-counter (OTC) intranasal naloxone product, Rextovy, a 4 milligram (mg) naloxone hydrochloride nasal spray for the emergen…
    fda_press · 1mo ago
  • Why isn’t alcohol seen as a public health emergency?
    Why isn't alcohol seen as a public health emergency? Alex Hogan talks to STAT's Isabella Cueto and Lev Facher about their new series on this week's STATus Report.
    stat · 3mo ago
view all news mentions →
brand
Fentanyl
generic
fentanyl
MOA
Mu opioid receptor agonist
indication
Cancer Pain
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 21m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?